Quick Answer
Maze Therapeutics, Inc. reported Net Income Loss of -$131.12 million for the year ending 2025.
- Maze Therapeutics, Inc. showed a decrease of -351.0% in Net Income Loss from 2024 to 2025.
- This data is from Maze Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$32.49 million | Q2 2024: $139.06 million | Q3 2024: -$24.75 million | Q1 2025: -$32.79 million | Q2 2025: -$33.68 million | Q3 2025: -$30.09 million.
- Historical annual values: Fiscal year 2025: -$131.12 million | Fiscal year 2024: $52.23 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: